Xue Wang
Xi'an Jiaotong University
23 Papers
41 Citations
Xue Wang is an academic researcher from Xi'an Jiaotong University. The author has contributed to research in topics: Medicine & Voriconazole. The author has an hindex of 9, co-authored 19 publications.
Chat about Author
Papers
Efficacy and safety of voriconazole and CYP2C19 polymorphism for optimised dosage regimens in patients with invasive fungal infections.
Taotao Wang,Huifang Zhu,Jinyao Sun,Xiaoliang Cheng,Xiaoliang Cheng,Jiao Xie,Haiyan Dong,Limei Chen,Xue Wang,Jianfeng Xing,Yalin Dong +10 more
TL;DR: It is highlighted that voriconazole C(min) and C(Min)/C(N) are strongly influenced by CYP2C19 polymorphism, and gene-adjusted dosing is important to achieve therapeutic levels that maximise therapeutic response and minimise hepatotoxicity.
107
Optimal tigecycline dosage regimen is urgently needed: results from a pharmacokinetic/pharmacodynamic analysis of tigecycline by Monte Carlo simulation
Jiao Xie,Taotao Wang,Jinyao Sun,Siying Chen,Jiangxia Cai,Weipeng Zhang,Haiyan Dong,Sasa Hu,Di Zhang,Xue Wang,Yalin Dong +10 more
TL;DR: In the absence of new drugs on the horizon, rather than using a single fixed dosing regimen, tigecycline dosing needs to be optimized in order to achieve the desired successful clinical response and to prevent an escalation in drug resistance.
53
Pharmacokinetic and Pharmacodynamic Properties of Oral Voriconazole in Patients with Invasive Fungal Infections
Taotao Wang,Jiao Xie,Yan Wang,Xiaowei Zheng,Jin'e Lei,Xue Wang,Haiyan Dong,Qianting Yang,Limei Chen,Jianfeng Xing,Yalin Dong +10 more
TL;DR: To assess the pharmacokinetic and pharmacodynamic (PK/PD) properties of voriconazole and to investigate the relationship between PK/PD parameters and the efficacy of a fixed‐dose oral regimen in the treatment of invasive fungal infections.
30
Pharmacokinetic/pharmacodynamic evaluation of linezolid for the treatment of staphylococcal infections in critically ill patients
TL;DR: Findings indicate that a strategy of high linezolid dosage may be needed to increase the probability of successful treatment at MIC > 1 mg/L, and the role of therapeutic drug monitoring should be encouraged for optimising lineZolid exposure in critically ill patients.
28
Risk Factors for Voriconazole-Associated Hepatotoxicity in Patients in the Intensive Care Unit
Yan Wang,Taotao Wang,Jiao Xie,Qianting Yang,Xiaowei Zheng,Weihua Dong,Jianfeng Xing,Xue Wang,Yalin Dong +8 more
TL;DR: To determine the incidence of hepatotoxicity in critically ill patients who were treated with voriconazole and to identify potential risk factors for vorIconazole‐associated hepatot toxicity in these patients.
18